Alterações hematológicas, hemostáticas e bioquímicas de cães tratados com anti-inflamatórios não esteroidais

• Ano de defesa: 2011
• Autor(a) principal: Marini Filho, Rivaldo
• Orientador(a): Melchert, Alessandra
• Banca de defesa: Balarin, Mara Regina Stipp , Laposy, Cecília Braga
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade do Oeste Paulista
• Programa de Pós-Graduação: Mestrado em Ciência Animal
• Departamento: Ciências Agrárias
• País: BR
• Palavras-chave em Português: anti-inflamatórios não-esteroidais; hematologia; coagulação; biomarcadores cardíacos; cão
• Palavras-chave em Inglês: monsteroidal drugs; hematology; coagulations; cardiac biomarkers; dogs
• Área do conhecimento CNPq: CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA
• Link de acesso: http://bdtd.unoeste.br:8080/tede/handle/tede/257

This study aimed to evaluate the heart and liver biomarkers, hematology and hemostasis in healthy dogs, submitted to therapy with nonsteroidal anti-inflammatory non-selective (NSAID), COX-2 preferential and COX-2 selective drugs. Were used 30 mongrel dogs, adults, males and females, clinically healthy, randomly divided into 5 groups (G) of 6 animals, that received the follow therapies: ketoprofen, nimesulide, meloxican, etodolac and celecoxib. The blood count, hemostatic profile (clotting time (CT), prothrombin time (PT), activated partial thromboplastin time (APTT), platelets and fibrinogen), cardiac biomarkers (CK, CKMB) and liver function (ALT, AST and albumin) were evaluate before, at 5 and 10 days (T0, T5, T10) of treatment in all treatment groups, and at 20 days (T20) treatment in celecoxib. The CT scan showed significant increase in the ketoprofen group at T5, while in the nimesulide group significantly increased at T10, in both groups when compared to T0. In TP, the etodolac group showed significant reduction in the T5 compared to T0, while the platelet count increased at T10 compared to T0 and T5 in the ketoprofen group. The red blood cells and Ht decreased in T10 compared to T0 in the ketoprofen group, while the reduction in the celecoxib group T20 compared to T0. The celecoxib group revealed decreased values of total leukocytes, neutrophils and lymphocytes in the T20. Significant increase in CKMB, LDH, and ALT were observed in the celecoxib group. Reduction of serum albumin occurred in the nimesulide and ketoprofen groups in T5 and T10 and T10, respectively. In conclusion, meloxican was the safest drug to NSAID therapy in dogs. The NSAIDs ketoprofen, nimesulide and etodolac should be used judiciously in patients with dysfunction of coagulation profile, once that promote increase in coagulation parameters. Celecoxib appears to be safe in relation to the coagulation, even under prolonged therapy. Celecoxib and ketoprofen therapy requires attention for use in anemic dogs because they are able to reduce the red series. Ketoprofen is contraindicated in patients with hypoalbuminemia. Long term celecoxib therapy should be used cautiously in dogs with immunosuppressive processes, since it was able to reduce the white blood cell counts.